Search
ASH 2025: CEO Will West describes how CellCentric is seeing results for its oral p300/CBP inhibitor, Inobrodib, in heavily refractory multiple myeloma patients
Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026. Coverage brought to you by
Dec 7
ASH 2024: Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma
CEO Will West describes how the company focuses on inhibiting the bromodomain of these targets with inobrodib, rather than the active...
Dec 7, 2024
.png){kind=logo}
